Vulvovaginal atrophy in the CRETA study : the healthcare professionals' perception
OBJECTIVES: The objective is to assess the perception of gynecologists regarding patients' adherence to vulvovaginal atrophy (VVA) treatments, to evaluate the gynecologists' opinions on what their patients think about treatment adherence, and to compare the gynecologists' opinions with the patients' own perceptions within the CRETA study.
METHODS: Spanish gynecologists who participated in the CRETA study were asked to fill out an online 41-item questionnaire to evaluate their views on VVA management.
RESULTS: From 29 centers across Spain, 44 gynecologists completed the survey. Their mean age was 47.2 years old, two-thirds of them were women, and the average professional experience was over 20 years. According to the gynecologists, the therapy most frequently used by VVA-diagnosed women was vaginal moisturizers (45.5%), followed by local estrogen therapy (36.4%) and ospemifene (18.2%). Nevertheless, ospemifene was viewed as the therapeutic option with the most efficacy, easiest route of administration, shorter time to symptom improvement, lower percentage of dropouts, and higher treatment adherence.
CONCLUSIONS: Spanish gynecologists are in general agreement with their patients regarding VVA treatment preferences and the main issues for adherence and effectiveness. However, there is an opportunity for doctor-patient communication improvement. Among the three therapeutic options evaluated, ospemifene is regarded as offering some competitive advantages.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology - 39(2023), 1 vom: 28. Dez., Seite 2264405 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cancelo, María J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.11.2023 Date Revised 04.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/09513590.2023.2264405 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363049770 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363049770 | ||
| 003 | DE-627 | ||
| 005 | 20231226092526.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/09513590.2023.2264405 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1210.xml |
| 035 | |a (DE-627)NLM363049770 | ||
| 035 | |a (NLM)37811796 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cancelo, María J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vulvovaginal atrophy in the CRETA study |b the healthcare professionals' perception |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.11.2023 | ||
| 500 | |a Date Revised 04.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: The objective is to assess the perception of gynecologists regarding patients' adherence to vulvovaginal atrophy (VVA) treatments, to evaluate the gynecologists' opinions on what their patients think about treatment adherence, and to compare the gynecologists' opinions with the patients' own perceptions within the CRETA study | ||
| 520 | |a METHODS: Spanish gynecologists who participated in the CRETA study were asked to fill out an online 41-item questionnaire to evaluate their views on VVA management | ||
| 520 | |a RESULTS: From 29 centers across Spain, 44 gynecologists completed the survey. Their mean age was 47.2 years old, two-thirds of them were women, and the average professional experience was over 20 years. According to the gynecologists, the therapy most frequently used by VVA-diagnosed women was vaginal moisturizers (45.5%), followed by local estrogen therapy (36.4%) and ospemifene (18.2%). Nevertheless, ospemifene was viewed as the therapeutic option with the most efficacy, easiest route of administration, shorter time to symptom improvement, lower percentage of dropouts, and higher treatment adherence | ||
| 520 | |a CONCLUSIONS: Spanish gynecologists are in general agreement with their patients regarding VVA treatment preferences and the main issues for adherence and effectiveness. However, there is an opportunity for doctor-patient communication improvement. Among the three therapeutic options evaluated, ospemifene is regarded as offering some competitive advantages | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Vulvovaginal atrophy | |
| 650 | 4 | |a genitourinary syndrome of menopause | |
| 650 | 4 | |a gynecologists’ perception | |
| 650 | 4 | |a gynecologist–patient relationship | |
| 650 | 4 | |a ospemifene | |
| 650 | 4 | |a surveys and questionnaires | |
| 650 | 4 | |a treatment adherence | |
| 650 | 7 | |a Ospemifene |2 NLM | |
| 650 | 7 | |a B0P231ILBK |2 NLM | |
| 650 | 7 | |a Tamoxifen |2 NLM | |
| 650 | 7 | |a 094ZI81Y45 |2 NLM | |
| 700 | 1 | |a Sánchez Borrego, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Palacios, Santiago |e verfasserin |4 aut | |
| 700 | 1 | |a Baquedano, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Corbacho Garza, Tanit |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández Aller, Noelia |e verfasserin |4 aut | |
| 700 | 1 | |a García Ferreiro, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Quijano Martín, Juan José |e verfasserin |4 aut | |
| 700 | 1 | |a González Calvo, A Javier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology |d 1996 |g 39(2023), 1 vom: 28. Dez., Seite 2264405 |w (DE-627)NLM013051202 |x 1473-0766 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2023 |g number:1 |g day:28 |g month:12 |g pages:2264405 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/09513590.2023.2264405 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2023 |e 1 |b 28 |c 12 |h 2264405 | ||